南方医科大学学报

南方医科大学学报 ›› 2021, Vol. 41 ›› Issue (8): 1214-1219.doi: 10.12122/j.issn.1673-4254.2021.08.13

• • 上一篇    下一篇

血浆SEPTIN9甲基化水平检测有助于食管癌诊断和放疗敏感性预测

孙巧玉，刘 佳，樊筱玓，周咏春，王效静，崔 珍   

  1. 蚌埠医学院第一附属医院放疗科，呼吸系病临床基础安徽省重点实验室//蚌埠医学院第一附属医院分子诊断中心，安徽 蚌埠 233000
  • 出版日期:2021-08-20 发布日期:2021-09-07

Value of plasma SEPTIN9 methylation detection for diagnosis and predicting radiosensitivity of esophageal carcinoma

SUN Qiaoyu, LIU Jia, FAN Xiaodi, ZHOU Yongchun, WANG Xiaojing, CUI Zhen   

  1. Department of Radiotherapy, Anhui Provincial Clinical and Preclinical Key Laboratory of Respiratory Disease//Molecular Diagnostic Center, First Affiliated Hospital of Bengbu Medical College, Bengbu 233000, China
  • Online:2021-08-20 Published:2021-09-07

RichHTML

34

PDF

367

摘要： 目的 探讨血浆mSEPT9对食管癌诊断的应用价值及其与放疗敏感性的关系。方法 选取2019年1月~2020年12月在蚌埠医学院第一附属医院放疗科接受根治性放疗的72例食管癌患者，运用PCR法分别检测患者放疗前及放疗后血浆mSEPT9，另以体检中心20例健康人作为对照。用受试者工作特征曲线（ROC曲线）评价mSEPT9对食管癌的诊断价值。用χ2检验分析mSEPT9与食管癌患者临床病理特征的关系。根据放疗疗效将食管癌患者分为放疗敏感组和不敏感组，比较放疗前两组患者mSEPT9差异。动态观察食管癌患者放疗前后mSEPT9变化，分别评价不同放疗敏感性组放疗前后mSEPT9差异。结果 mSEPT9诊断食管癌的灵敏度为62.5%，特异度为100%，ROC曲线下面积为0.813。mSEPT9与食管癌患者淋巴结转移、临床分期有关（P<0.05），与性别、年龄、侵犯部位、肿瘤长度、分化程度、浸润程度等无关（P>0.05）。放疗敏感组mSEPT9阳性率低于放疗不敏感组（53.06% vs 82.61%，P=0.016）。72例患者放疗后mSEPT9阳性率较放疗前显著下降（30.56% vs 62.5%，P<0.001），其中放疗敏感组放疗后mSEPT9阳性率较放疗前显著下降（14.29% vs 53.06%，P<0.001），不敏感组放疗后mSEPT9阳性率较放疗前无显著性差异（65.22% vs 82.61%，P=0.125）。结论 检测血浆mSEPT9有助于食管癌患者诊断和放疗敏感性预测。

关键词: mSEPT9；食管癌；诊断；放疗敏感性

Abstract: Objective To investigate the value of plasma mSEPT9 detection in the diagnosis and prediction of radiosensitivity of esophageal carcinoma. Methods This study was conducted in 72 patients with esophageal cancer who received radical radiotherapy in the Department of Radiotherapy of First Affiliated Hospital of Bengbu Medical College between January, 2019 and December, 2020. Plasma mSEPT9 of the patients were examined with PCR before and after radiotherapy, with 20 healthy subjects from the physical examination center as the controls. The receiver operating characteristic curve (ROC) was used to assess the value of mSEPT9 in diagnosis of esophageal cancer, and the correlation between mSEPT9 and clinicopathological characteristics of the patients was analyzed. According to their response to radiotherapy, the patients were divided into radiosensitive group and insensitive group, and their plasma mSEPT9 levels were compared before radiotherapy. All the patients were observed for dynamic changes of mSEPT9 levels after radiotherapy to analyze the association of mSEPT9 variation with radiosensitivity of the tumors. Results The sensitivity and specificity of mSEPT9 for the diagnosis of esophageal carcinoma were 62.5% and 100%, respectively, with an area under the ROC curve of 0.813. Plasma mSEPT9 level was correlated with lymph node metastasis and clinical stages of esophageal carcinoma (P<0.05), but not with gender, age, invasion site, tumor length, degree of differentiation, or depth of invasion (P>0.05). The radiosensitive patients had a significantly lower positivity rate for mSEPT9 than the insensitive patients before radiotherapy (53.06% vs 82.61%, P=0.016). In the 72 patients, the positivity rate for mSEPT9 decreased significantly after radiotherapy (30.56% vs 62.5% , P<0.001); the positivity rate was significantly lowered after radiotherapy in the radiosensitive group (14.29% vs 53.06% , P<0.001), but the reduction was not significant in the insensitive group (65.22% vs 82.61%, P=0.125). Conclusion Detection of plasma mSEPT9 level is helpful for diagnosis and prediction of radiosensitivity of esophageal carcinoma.

Key words: mSEPT9; esophageal carcinoma; diagnosis; radiosensitivity